The partners will use Tyris' nonviral-based gene therapy technology and Almirall's expertise in medical dermatology to develop next-generation gene therapies for rare genetic dermatology diseases. Tyris' nonviral DNA-based technology aims to deliver genes without size restrictions to specific tissues with the option for readministration. The company expects that preexisting immunity or development of immune response against the vector will not be an issue. The technology only requires the DNA sequence for therapeutic effect and does not carry any additional unwanted elements.

The companies will collaborate closely during the partnership. Tyris will be responsible for generating clinical lead candidates and progress them to clinical development. Tyris will receive an upfront payment and research milestone payments along with research funding from Almirall. In exchange, Almirall will have exclusive options to acquire gene therapy products and progress them through clinical development and commercialization.

The financial terms of the collaboration were not disclosed.